Investigational drug · Phase 3
H2 receptor antagonist
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
88
Any phase or sponsor naming "H2 receptor antagonist"
First trial start
2023
May 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "H2 receptor antagonist", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Neoplasm Malignant
- Esophageal Squamous Cell Carcinoma
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "H2 receptor antagonist" as an intervention, largest first.
Canadian Network for Observational Drug Effect Studies, CNODESAcademic, hospital or other
NCT02555852 · 4,238,504 participants · Start Sep 2011 · Primary completion Feb 2012
Drug: esomeprazole; omeprazole and 13 more · For: Gastroesophageal Reflux Disease (GERD); Community-acquired Pneumonia
Sites: Montreal, Canada
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06393374 · 1,530 participants (planned) · Start Jun 24, 2024 · Primary completion Dec 16, 2030
Drug: Pembrolizumab; Sacituzumab tirumotecan and 1 more · For: Triple-Negative Breast Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Fountain Valley, California · 317 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216703 · 1,023 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 29, 2031
Drug: Pembrolizumab; Sacituzumab Tirumotecan and 5 more · For: Cervical Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Irvine, California · 189 sites in all
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06841354 · 1,000 participants (planned) · Start Mar 16, 2025 · Primary completion May 18, 2030
Drug: Sacituzumab tirumotecan; Pembrolizumab and 5 more · For: Triple Negative Breast Neoplasms
Sites: Mobile, Alabama; Chandler, Arizona; Duarte, California · 285 sites in all
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07318558 · 900 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 25, 2033
Drug: Sacituzumab tirumotecan; Bevacizumab and 1 more · For: Ovarian Neoplasms; Ovarian Cancer
Sites: Birmingham, Alabama; La Jolla, California; Newport Beach, California · 178 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06312137 · 780 participants (planned) · Start Apr 3, 2024 · Primary completion Feb 21, 2034
Drug: Sacituzumab tirumotecan; Pembrolizumab and 6 more · For: Non Small Cell Lung Cancer
Sites: Little Rock, Arkansas; Springdale, Arkansas; Beverly Hills, California · 271 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06824467 · 770 participants (planned) · Start Apr 9, 2025 · Primary completion Apr 27, 2029
Drug: Sacituzumab tirumotecan; Bevacizumab and 5 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Duarte, California · 203 sites in all
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06132958 · 710 participants (planned) · Start Dec 6, 2023 · Primary completion Jan 10, 2028
Drug: Sacituzumab tirumotecan; Doxorubicin and 3 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 242 sites in all
- Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)Pivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT00247715 · 664 participants · Start Oct 2003
Drug: algeldrate/magnesium oxide; ranitidine and 1 more · For: Dyspepsia; Gastrointestinal Diseases
Sites: Nijmegen, Netherlands; Maastricht, Netherlands; Utrecht, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Reconsidering the Mechanism of Proton Pump Inhibitor-Associated Fundic Gland Polyps: Absence of Re-enlargement during Potassium-Competitive Acid Blocker Therapy.
Misumi Y, Marumo T, Ban S, et al. · DEN Open 2027
- Proton pump inhibitor use is associated with increased complications compared to H2-receptor antagonists following multi-level lumbar fusion: a retrospective cohort study.
Patel U, B Madera R, Kim J, et al. · Eur Spine J 2026
- Hospital costs for infants with brief resolved unexplained events given a diagnosis of gastroesophageal reflux disease.
Duncan DR, Liu E, Growdon AS, et al. · J Pediatr Gastroenterol Nutr 2026
- Ranitidine attenuates myocardial fibrosis by suppressing histamine/H2 receptor signaling and FAK/Src activation.
Yang L, Zhang J, Zhao J, et al. · Front Pharmacol 2026
- Potassium-Competitive Acid Blocker-Associated Gastric Hyperplastic Polyps With Severe Bleeding: A Case Series.
Kasuga K, Katakai S, Shimizu M, et al. · DEN Open 2026
Also in development for Lung Neoplasm Malignant
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- MK-1084CalderasibPhase 38 trials
Merck & Co. · Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.